QIAGEN opens Shared Services Center in Taguig City, Manila

MANILA, February 23, 2018 – QIAGEN N.V. today announced the opening of QIAGEN Business Services (QBS) Manila, its new Shared Service Center in the Philippines. The new location in the Cyber Sigma building in Fort Bonifacio, Taguig City, Manila, was officially opened today by Roland Sackers, Chief Financial Officer of QIAGEN, in a ceremony that... Read more

Health Canada licenses four prenatal screening assays for risk assessment of fetal trisomies and pre-eclampsia

Health Canada licenses four prenatal screening assays for risk assessment of fetal trisomies and pre-eclampsia B·R·A·H·M·S Biomarkers Receive Class III Medical Device System License for Prenatal Screening WALTHAM, Mass., Feb. 15, 2018 /PRNewswire/ — B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific Inc., today announced that its sFlt-1, PlGF plus, PAPP-A and Free βhCG KRYPTOR... Read more

BD Completes Asset Divestitures to Merit Medical

FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira® product line to Merit Medical Systems, Inc. following receipt of all required regulatory... Read more

SCMI Consortium chooses JEOL JEM-Z300FSC CRYO ARM™ 300

The Scottish Cryo-EM consortium has chosen the JEOL JEM-Z300FSC CRYO ARM™ 300 as their preferred automated Cryo Transmission Electron Microscope (Cryo-TEM) for the Scottish Centre for Macromolecular Imaging (SCMI). Further information: JEOL UK press release Also See: CRYO ARM™ 200 Field Emission Cryo-electron MicroscopeCRYO ARM™ 300 Field Emission Cryo-electron Microscope # # # JEOL USA,... Read more

QIAGEN’s QuantiFERON-TB Gold Plus gains approval in Japan

Hilden, Germany, and Tokyo, Japan, February 8th, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Japan’s Ministry of Health Labor and Welfare has approved QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic to detect tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining innovative... Read more

Agilent to Support Korea Doping Control Center

Agilent to Support Korea Doping Control Center Facility to test urine samples from thousands of athletes SANTA CLARA, Calif., Feb. 8, 2018 Agilent Technologies Inc. (NYSE: A) today announced it will collaborate with the Doping Control Center in Seoul, South Korea, to ensure that athletes from around the world are quickly and accurately tested to... Read more

International Olympic Committee and GE Healthcare Launch Analytics Tool to Help Drive Precision Health at the Olympic Winter Games

The GE Athlete Management Solution (AMS) collects multiple kinds of data, including imaging scans, patient vitals, and venue, event and sport-specific information, and provides real-time dashboards that can help inform medical staff and allow them to personalize treatment for athletes while identifying trends in injury and illness across the Games. For example, the tool can... Read more

A GE HEALTHCARE MAGYAR ÉS AMERIKAI IT SZAKEMBEREI FEJLESZTETTÉK A TÉLI OLIMPIA SPORTORVOSI ANALITIKAI RENDSZERÉT

Az alkalmazás olyan értékes információkat tesz elérhetővé egy helyen és felületen, mint például a sportoló sérüléseinek és betegségének adatai, a helyszín adatai, az alkalmazott sport- és edzési- eljárások. A felhőben tárolt információk alapján a Játékok egészségügyi személyzete átfogó képet kaphat a sportolók egészségi állapotáról, és gyors döntéseket hozhat a szükséges beavatkozás, vagy kezelés módjáról. Az... Read more

Comparable Historical Revenue Schedules Inclusive of C. R. Bard Posted to BD Website

FRANKLIN LAKES, N.J., Feb. 2, 2018 /PRNewswire/ — As previously disclosed, on December 29, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX) completed the acquisition of C. R. Bard, Inc. (“Bard”).  In relation to the acquisition, BD has provided supplemental, unaudited historical financial information on the Investor page of its website at www.bd.com/investors.  This information presents... Read more